Nature Communications (Nov 2022)
Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
Abstract
Few countries have approved SARS-CoV-2 booster doses in children and adolescents due to insufficient evidence about the safety and interval vaccination. Here, the authors assess the safety and immunogenicity of a homologous booster dose of CoronaVac in a cohort of 3–17 year olds.